1. Choi SS, Han KJ, Lee JK, et al. Antinociceptive mechanisms of orally administered decursinol in the mouse. Life Sci. 2003 Jun 13;73(4):471-85.
2. Choi SS, Han KJ, Lee HK, Han EJ, Suh HW. Antinociceptive profiles of crude extract from roots of Angelica gigas NAKAI in various pain models. Biol Pharm Bull. 2003 Sep;26(9):1283-8.
3. Kim JH, Jeong JH, Jeon ST, et al. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages. Mol Pharmacol. 2006 Jun;69(6):1783-90.
4. Lee JH, Jung HS, Giang PM, et al. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J Pharmacol Exp Ther. 2006 Jan;316(1):271-8.
5. Chun YS. Clinical study of GWB78 as a pain-killer with chronic degenerative joint arthritis and cervicoomobrachial syndrome patients. Mapo Pain Clinic, Seoul, South Korea. 2001 Nov. Unpublished study sponsored by Scigenics, Co., Ltd.
6. Kim HH, Ahn KS, Han H, et al. Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells. Leuk Res. 2005 Dec;29(12):1407-13.
7. Yim D, Singh RP, Agarwal C, et al. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005 Feb 1;65(3):1035-44.
8. Guo J, Jiang C, Wang Z, et al. A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer Ther. 2007 Mar;6(3):907-17.
9. Jiang C, Lee HJ, Li GX, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006 Jan 1;66(1):453-63.
10. Han SB, Lee CW, Kang MR, et al. Pectic polysaccharide isolated from Angelica gigas Nakai inhibits melanoma cell metastasis and growth by directly preventing cell adhesion and activating host immune functions. Cancer Lett. 2006 Nov 18;243(2):264-73.
11. Kim HH, Sik BS, Seok CJ, Han H, Kim IH. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett. 2005 Jun 8;223(2):191-201.
12. Yan JJ, Kim DH, Moon YS, et al. Protection against beta-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):25-30.
13. Kang SY, Lee KY, Sung SH, Kim YC. Four new neuroprotective dihydropyranocoumarins from Angelica gigas. J Nat.Prod. 2005 Jan;68(1):56-9.
14. Kang SY, Lee KY, Park MJ, et al. Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol Learn Mem. 2003 Jan;79(1):11-8.
15. Kang SY, Lee KY, Sung SH, Park MJ, Kim YC. Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: structure-activity relationships. J Nat Prod. 2001 May;64(5):683-5.
16. Kang SY, Lee KY, Koo KA, et al. ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice. Life Sci. 2005 Feb 25;76(15):1691-705.
17. Sarker SD, Nahar L. Natural medicine:
the genus Angelica. Curr Med Chem. 2004 Jun;11(11):1479-500.
18. Available at: http://www.phytochemicals.info/plants. Accessed April 27, 2007.
19. Lee YY, Lee S, Jin JL, Yun-Choi HS. Platelet anti-aggregatory effects of coumarins from the roots of Angelica genuflexa and A. gigas. Arch Pharm Res. 2003 Sep;26(9):723-6.
20. Available at: http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cou1103.shtml. Accessed May 9, 2007.
21. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):87-93.
22. Available at: http://www.pdrhealth.com/drug_info/otcdrugprofiles/drugs/fgotc011.shtml. Accessed May 7, 2007.
23. Stillman MJ, Stillman MT. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics. 2007 Feb;62(2):26-34.